Study: NCT00473083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 2% in hydrocortisone 1% lotion
Description: Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 2% in hydrocortisone 1% lotion
Description: Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 2% in hydrocortisone 1% lotion
Description: Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
Description: Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
Description: Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
Description: Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water